Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
MGNX
MGNX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
MGNX News
Incyte's Cancer Therapy Zynyz Receives EMA Endorsement for New Indication
Jan 30 2026
seekingalpha
After-Hours Movers: MGNX, SLS, KRMD, HYPR, WVE Experience Significant Changes After Q3 Reports
Nov 13 2025
NASDAQ.COM
MacroGenics Revenue Doubles in Q2
Aug 14 2025
NASDAQ.COM
OrganiGram (OGI) Reports Q3 Loss, Beats Revenue Estimates
Aug 13 2025
NASDAQ.COM
MacroGenics signs financial deal with Sagard for retifanlimab
Jun 10 2025
SeekingAlpha
MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase Agreement
Jun 10 2025
Newsfilter
4 Analysts Assess Macrogenics: What You Need To Know
May 20 2025
Benzinga
MacroGenics to Participate in Upcoming Investor Conference
May 01 2025
Newsfilter
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Sanofi (OtherSNYNF) and MacroGenics (MGNX)
Mar 24 2025
Business Insider
Why AZEK Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
Mar 24 2025
Benzinga
MacroGenics (MGNX) Gets a Hold from TD Cowen
Mar 20 2025
Business Insider
Here are the major earnings after the close today
Mar 20 2025
SeekingAlpha
MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call
Mar 06 2025
Newsfilter
Investigation Alert: MacroGenics, Apellis Pharmaceuticals, Teradata and Maplebear - Johnson Fistel, LLP Encourages Long-Term Investors to Reach Out for More Information
Feb 06 2025
Globenewswire
Validea Kenneth Fisher Strategy Daily Upgrade Report - 12/11/2024
Dec 11 2024
NASDAQ.COM
MGNX ALERT: Bragar Eagel & Squire, P.C. is Investigating Macrogenics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Dec 10 2024
Globenewswire
Show More News
